Weekly topotecan for platinum resistant ovarian cancer

摘要: 15040 Background: Topotecan is currently used to treat recurrent ovarian cancer after failure of platinum-based therapy. The FDA-recommended regimen (1.5 mg/m2 for 5 consecutive days a 21-day cycle) associated with high incidence grade 3/4 myelosuppression. Alternate dosing and scheduling may increase patient convenience reduce toxicity. objective this study evaluate toxicity, response progression free survival weekly topotecan therapy in women primary secondary platinum resistant 1 or more regimens. Methods: A retrospective analysis 59 patients that received median dose 3.75 on 1, 8, 15 28-day cycle treated between November 2002 May 2005. All had epithelial resistance platinum. Disease was evaluated by CA-125 levels, physical exam, when appropriate imaging studies. Toxicity using the NCI Com...